Dyne Therapeutics, INC Form 4 insider transactions

Dyne Therapeutics director Dirk Kersten sold 129,672 shares of common stock for approximately $19.52 per share under a pre-arranged trading plan.

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, sold 148 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 904 shares of common stock to cover tax withholding obligations related to RSU vesting.

Dyne Therapeutics CEO John Cox sold 2,732 shares of common stock at $14.90 per share to cover tax withholding obligations related to restricted stock unit vesting.

Dyne Therapeutics director Vikram Karnani was granted 59,665 stock options with an exercise price of $20.78, vesting over three years.

Dyne Therapeutics CEO John Cox sold 2,662 shares of common stock at a weighted average price of $20.72 to cover tax withholding obligations related to RSU vesting.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 880 shares of common stock at a weighted average price of $20.72 to cover tax withholding obligations from RSU vesting.

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, sold 144 shares of common stock at a weighted average price of $20.72 to cover tax withholding obligations related to RSU vesting.

Dyne Therapeutics Director Brian S. Posner was granted 70,000 stock options with an exercise price of $12.5, vesting over three years.

Dyne Therapeutics CEO John Cox sold 2,640 shares of common stock at $13.41 per share to cover tax withholding from RSU vesting, also remitting short-swing profits.

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, sold shares to cover tax liabilities from RSU vesting, as per pre-arranged Rule 10b5-1 plans.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold common stock totaling 4,425 shares to cover tax withholding obligations from RSU vesting.

Dyne Therapeutics, Inc. has granted 51,255 performance-based stock options to Chief Commercial Officer Johanna Friedl-Naderer, exercisable at $9.33 per share and subject to a $20.00 stock price target or change in control.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, was granted 65,110 performance-based stock options with an exercise price of $9.33, contingent on the stock reaching $20.00 within three years.

Dyne Therapeutics, Inc. CEO John Cox received a grant of 197,285 performance-based stock options with an exercise price of $9.33, contingent on the company's stock reaching $20.00.

Dyne Therapeutics CEO John Cox reported a significant share purchase, subsequent gifts to family trusts, and a payment to the company to resolve a short-swing profit violation under Section 16(b) of the Exchange Act.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 1,342 shares of common stock for $13.35 per share to cover tax withholding obligations related to restricted stock unit vesting, as part of a pre-arranged 10b5-1 plan.

Dyne Therapeutics CEO John Cox sold 4,060 shares of common stock on June 5, 2025, at a weighted average price of $13.35 per share, to satisfy tax withholding obligations related to restricted stock unit vesting.

Dyne Therapeutics, Inc.'s Chief Commercial Officer, Johanna Friedl-Naderer, sold 146 shares of common stock at a weighted average price of $13.35 per share to cover tax withholding obligations related to restricted stock unit vesting.

Dyne Therapeutics, Inc. Director Edward Hurwitz was granted 35,000 stock options with an exercise price of $11.96, vesting by May 2026 or the 2026 Annual Meeting.

Dyne Therapeutics, Inc. Director David Charles Lubner was granted 35,000 stock options with an exercise price of $11.96, vesting fully by May 2026.

Dyne Therapeutics, Inc. Director Jason P. Rhodes was granted 35,000 stock options with an exercise price of $11.96, vesting on the earlier of May 30, 2026, or the 2026 Annual Meeting of Stockholders.

Dyne Therapeutics, Inc. Director Dirk Kersten was granted 35,000 stock options with an exercise price of $11.96, vesting by May 2026.

Dyne Therapeutics, Inc. Director Carlo Incerti was granted 35,000 stock options with an exercise price of $11.96, vesting in 2026.

Dyne Therapeutics, Inc. Director Catherine Stehman-Breen was granted 35,000 stock options with an exercise price of $11.96, vesting by May 2026.

Chief Financial Officer Erick Lucera reports the acquisition of restricted stock units and stock options in Dyne Therapeutics.

Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, sold 143 shares of common stock on March 13, 2025, to cover tax obligations related to vesting restricted stock units.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 1,343 shares of common stock to cover tax obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,153 shares of common stock to cover tax obligations related to vesting restricted stock units.

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, sold 1,343 shares of common stock on March 5, 2025, to cover tax obligations related to vesting restricted stock units.